Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Q3 2025 Earnings Presentation
23 slides from Invivyd's earnings presentation, Nov 6, 2025
Slide 1: Invivyd Q3 Earnings Call & Business Update
Exhibit 99.2 Invivyd Q3 Earnings Call & Business Update November 6, 2025 © 2025 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners. 1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Agenda
01 Invivyd Approach 02 Clinical & Regulatory 03 Future Commercial Landscape agenda 04 Finance 05 Q&A 3
Slide 4: Developing best-in-class antibody therapies across multiple viral threats
We’re developing potential best- in-class antibody therapies across The need multiple viral threats, providing protection and defining what’s next in keeping people well. With is urgent. a broad pipeline and sharp execution, we’re moving quickly to turn breakthrough science into lasting impact and v
Slide 5: Clinical & Regulatory
01 Invivyd Approach 02 Clinical & Regulatory 03 Future Commercial Landscape agenda 04 Finance 05 Q&A 5
Slide 6: The Clinical Data
The Clinical Data Phase 3 RCTs: ~2 months of efficacy follow-up Current Disconnected The FDA Labels state of COVID “Once – OR – More than 2 months since last boost dose” mRNA vaccine prevention General Utilization Approximately annual 6 References: Prescribing Information – COMIRNATY Aug 2025; Presc
Slide 7: VYD2311 Study Designs
Day 90 Day 1 Day 30 Day 60 End of Study 60-Day Treatment Period 30-Day Follow-up Period VYD2311 Placebo Placebo VYD2311-SD (single dose) R VYD2311 VYD2311 VYD2311 VYD2311-MD Screening 1:1:1 (multidose) (up to Day -14) N1770 Placebo Placebo Placebo Placebo Monitor for CLI symptoms: Day 1 to Day 90 If
Slide 8: Why study safety and titer VYD2311 in multi-doses?
Repeat dose Why study safety and titer VYD2311 in multi-doses? data Anticipate that, if approved, most people would choose to get VYD2311 once a year, with a safety profile that enables extra protection for those who want it.* 8 *Depending on Prescribing Information, if approved
Slide 9: mRNA COVID vaccine side effects vs Invivyd antibodies
mRNA COVID vaccines Invivyd COVID IM antibodies side effects expected side effects High likelihood Low likelihood and and High discomfort Low discomfort 9
Slide 10: Future Commercial Landscape
01 Invivyd Approach 02 Clinical & Regulatory 03 Future Commercial Landscape agenda 04 Finance 05 Q&A 10
Slide 11: Foundation built to expand to a broad market
Foundation built to expand to a broad market Quick pivot from infused specialty medication to potential vaccine replacement PEMGARDA Net Established Strong Commercial Foundation $13.1 M Revenue Q3 ‘25 In-line commercial team and Continued sales growth QoQ in infrastructure to support long-term 2025
Slide 12: Broad recognition from Societies and Guidelines for Antibodies in COVID
Broad recognition from Societies and Guidelines for Antibodies in COVID SOCIETY / GUIDELINE PEMGARDA OR MAB TARGET AUDIENCE HIV.gov PEMGARDA Immunodeficiency IDSA Pemivibart Infectious disease NCCN – B-Cell Lymphomas Pemivibart Oncology NCCN – Infection Prevention Pemivibart Oncology Immune Deficien
Slide 13: COVID's systemic complications continue to unfold
COVID’s systemic complications continue to unfold All trademarks and logos displayed are the property of their respective owners. Their use here is for identification purposes only and does not constitute endorsement or affiliation. 13
Slide 14: Tailwinds for VYD2311
mRNA safety concerns from regulators and patients 1 Current Unique non-vaccine MOA to prevent COVID provides 2 a competitive and compelling differentiator market offers Significant unmet need for vaccine alternatives 3 tailwinds for Total addressable market is significant VYD2311 4 Growing identific
Slide 15: COVID information-sharing tactics are scalable
COVID information-sharing tactics are scalable 15
Slide 16: Commercial Congress activity
Commercial Congress activity 36 Congresses Planned 3 with expanded booth presence (20x20) • ASH, IDWeek, ACR Broad Focus: • Cardiology • Infectious Disease • Neurology • Nephrology • Pulmonology • Rheumatology • Transplant 16
Slide 17: U.S. population COVID and flu vaccination
U.S. Pop 12+ 293,000,000 Flu Vaccine doses in 147M 24-25 flu season 34.2M ~146 - 158M ~100 - 112M COVID vaccinated last Received a flu shot, but not COVID last Did not receive COVID or flu shot in last respiratory season respiratory season respiratory season 17
Slide 18: Goal: provide Americans with a choice for COVID protection
GOAL: provide Americans with a choice for COVID protection COVID-19 Vaccine Monoclonal Antibody: VYD2311 Reactogenic Not a vaccine Immunologically silent Myocarditis risk Short duration of protection Natural, supplemental protection (weeks) Long duration of protection Modest efficacy (months) Was ma
Slide 19: COVID Vaccines: Big Revenue, Small Protection
COVID Vaccines: Big Revenue, Small Protection 18 and over vaccine efficacy (VE) reduction in hospitalization estimate from CDC 2023–2024 vaccine dose, ≥7 days 36% $3.8B 7–59 days earlier 51% (45–56) FY24 60–119 days earlier 42% (35–48) U.S. Revenue 120–179 days earlier 15% (3–26) 19
Slide 20: Finance
01 Invivyd Approach 02 Clinical & Regulatory 03 Future Commercial Landscape agenda 04 Finance 05 Q&A 20
Slide 21: Financial highlights Q3 2025
Financial highlights Q3 2025 PEMGARDA® (pemivibart) net product revenue of $13.1 million • 41% growth over Q3 2024 • 11% growth over Q2 2025 October 2025 ending cash of over $100M • Ended Q3 2025 with $85.0 million in cash and cash equivalents after closing of $57.5 million public offering in August
Slide 22: Q&A
01 Invivyd Approach 02 Clinical & Regulatory 03 Future Commercial Landscape agenda 04 Finance 05 Q&A 22
Slide 23: Invivyd
INVIVYD